Sino Biopharmaceutical Limited (SBHMY) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Wan Chai, Hong Kong. The current CEO is S. Y. Tse.
SBHMY has IPO date of 2017-09-05, 24,379 full-time employees, listed on the Other OTC, a market capitalization of $14.2B.
Sino Biopharmaceutical Limited is an investment holding company and research and development pharmaceutical conglomerate headquartered in Hong Kong, operating primarily in the People's Republic of China. The company develops and commercializes a diverse portfolio of pharmaceutical products across multiple therapeutic areas, including oncology, cardio-cerebral vascular, hepatitis, orthopedic, and respiratory medicines, as well as advanced chemical formulations and generic pharmaceuticals. Beyond pharmaceutical manufacturing, the company operates an integrated healthcare ecosystem encompassing hospital operations, pharmaceutical distribution, optometry services, health food production, medical device development, and health information consultancy. Through its three main business segments—Modernised Chinese Medicines and Chemical Medicines, Investment, and Others—Sino Biopharmaceutical serves patients and healthcare providers across China with both traditional and contemporary therapeutic solutions. The company was incorporated in 2000 and maintains a comprehensive value chain from research and development through distribution and patient care services.
